10-Q: ADC Therapeutics Q1 2026: Revenue Up, R&D Down

ADC Therapeutics reported a 15.1% increase in net product revenue for Q1 2026, driven by higher sales volume and pricing, while R&D expenses decreased significantly due to restructuring.

Summary

• For the three months ended March 31, 2026, ADC Therapeutics reported total revenue of $20.85 million, a decrease of 9.5% compared to $23.03 million in the same period of 2025.
• Product revenues, net, increased by 15.1% to $20.03 million in Q1 2026 from $17.40 million in Q1 2025, attributed to higher sales volume and pricing.
• License revenues and royalties decreased by 85.5% to $0.82 million in Q1 2026 from $5.63 million in Q1 2025, primarily due to a one-time milestone payment recognized in the prior year.
• Operating expenses decreased by 10.5% to $46.10 million in Q1 2026 from $51.50 million in Q1 2025.
• Cost of product sales increased by 75.4% to $3.62 million in Q1 2026 from $2.06 million in Q1 2025.
• Research and development expenses decreased by 31.3% to $19.88 million in Q1 2026 from $28.93 million in Q1 2025, largely due to the 2025 Restructuring and discontinuation of certain programs.
• Selling and marketing expenses increased by 20.4% to $12.71 million in Q1 2026 from $10.55 million in Q1 2025.
• General and administrative expenses remained relatively flat, decreasing slightly by 0.6% to $9.90 million in Q1 2026 from $9.96 million in Q1 2025.
• The net loss for Q1 2026 was $32.97 million, an improvement from a net loss of $38.60 million in Q1 2025.
• Basic and diluted loss per share improved to $(0.21) in Q1 2026 from $(0.36) in Q1 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with strong product revenue growth offset by a decline in other revenue streams and continued net losses. The cost reductions are positive, but the ongoing need for capital remains a key concern.

Positives

• Net product revenue increased by 15.1% to $20.03 million in Q1 2026 compared to $17.40 million in Q1 2025, driven by higher sales volume and pricing.
• Significant reduction in Research and Development expenses by 31.3% to $19.88 million in Q1 2026 from $28.93 million in Q1 2025, due to restructuring and program prioritization.
• Net loss improved by 14.6% to $32.97 million in Q1 2026 from $38.60 million in Q1 2025.
• Basic and diluted loss per share improved to $(0.21) in Q1 2026 from $(0.36) in Q1 2025.
• Cash and cash equivalents stood at $231.0 million as of March 31, 2026, which management believes is sufficient for at least the next twelve months.
• The fair value of the HCR warrant obligation decreased, resulting in a $2.23 million gain recognized in 'Other, net' for Q1 2026.

Negatives

• Total revenue decreased by 9.5% to $20.85 million in Q1 2026 from $23.03 million in Q1 2025, primarily due to a significant drop in license revenues and royalties.
• Cost of product sales increased substantially by 75.4% to $3.62 million in Q1 2026 from $2.06 million in Q1 2025.
• Selling and marketing expenses increased by 20.4% to $12.71 million in Q1 2026 from $10.55 million in Q1 2025.
• The company continues to incur substantial net losses and expects to continue doing so for the foreseeable future, requiring additional capital.
• The deferred royalty obligation remains a significant liability at $304.69 million as of March 31, 2026.

Risks

• The company has incurred substantial net losses since inception and expects to continue incurring losses, necessitating additional capital raises.
• Indebtedness under the loan agreement with Oaktree Capital Management and Owl Rock Capital Advisors includes restrictive covenants.
• The Amended HCR Agreement negatively impacts cash generated from sales and licensing of ZYNLONTA and attractiveness as an acquisition target.
• Uncertainties related to international trade policies, including tariffs and sanctions.
• Risks associated with completing clinical trials on expected timelines, if at all, and the sufficiency of trial results.
• Potential for undesirable side effects or adverse events of products and product candidates.
• Challenges in obtaining and maintaining regulatory approval for products and product candidates.
• Difficulties in successfully commercializing products and securing adequate reimbursement.
• Complexity and difficulty in manufacturing products and product candidates.
• Substantial competition in the industry from new technologies and therapies.
• Reliance on third parties for clinical trials, manufacturing, and commercialization activities.
• Ability to obtain, maintain, and protect intellectual property rights.
• Potential product liability lawsuits and product recalls.
• The company's ability to fund its operations and execute its business plan depends on financial, economic, and market conditions, as well as the number of authorized shares.

Future Outlook

The company expects its research and development expenses to decrease in fiscal year 2026 compared to 2025 due to the 2025 Restructuring and expected reduction in spending on discontinued programs. Thereafter, R&D expenses may fluctuate based on clinical trial progress, regulatory processes, and manufacturing costs. The company believes its current cash position is sufficient for at least the next twelve months and plans to fund operations through existing cash, ZYNLONTA revenues, potential milestone payments, and additional financing (equity, debt, collaborations).

Management Comments

• The company is pursuing expansion of ZYNLONTA internationally and into earlier lines of DLBCL, as well as into indolent lymphomas.
• Management believes its current cash position and capital resources are sufficient to fund operations and meet capital requirements for at least the next twelve months.
• The company is continuously exploring strategic collaborations, business combinations, licensing opportunities, or similar strategies for clinical development and commercialization.

Industry Context

StockSavvy.ai notes that ADC Therapeutics' Q1 2026 results reflect a common trend in the biopharmaceutical sector: increased product revenue driven by commercialization efforts, alongside significant R&D investment and restructuring to optimize resource allocation. The decrease in license revenue and royalties is typical for companies with strategic partnerships, as upfront payments and milestones are often lumpy. The continued focus on ZYNLONTA's expansion and pipeline advancement aligns with industry efforts to develop targeted therapies for challenging diseases like DLBCL.

Comparison to Industry Standards

• Compared to other commercial-stage biopharmaceutical companies focused on oncology, ADC Therapeutics' product revenue growth of 15.1% in Q1 2026 is a positive indicator of market adoption for ZYNLONTA.
• The significant reduction in R&D spending (31.3%) aligns with industry practices of cost optimization and portfolio prioritization following restructuring events, as seen in companies like Xencor or Seagen prior to its acquisition.
• The continued net loss is typical for companies in the clinical and commercial development phase of novel therapies, where substantial investment is required before achieving profitability. Many peers, such as Immunomedics before its acquisition, also operated with significant losses during their growth phases.
• The company's cash runway of at least twelve months is a critical metric for biotechs. While $231 million provides some buffer, it is subject to the company's burn rate and ability to secure future funding, a common challenge across the industry.

Legal Proceedings

• As of the date of the report, the company does not believe it is party to any claim or litigation that would reasonably be expected to have a material adverse effect on its business.

Stakeholder Impact

• Shareholders: Continued net losses and the need for potential future capital raises may impact share value. Improved loss per share is a positive sign.
• Employees: The 2025 Restructuring involved a workforce reduction of approximately 30%, impacting affected employees. Share-based compensation continues to be a component of employee remuneration.
• Creditors: The company has significant debt obligations, including a senior secured term loan and a deferred royalty obligation, which are being serviced.
• Partners/Collaborators: The company has ongoing strategic agreements for ZYNLONTA development and commercialization, with potential for milestone and royalty payments.

Next Steps

• Pursuing expansion of ZYNLONTA internationally and into earlier lines of DLBCL through LOTIS-5 and LOTIS-7 clinical trials.
• Advancing ZYNLONTA into indolent lymphomas, including marginal zone lymphoma (MZL) and follicular lymphoma (FL), through investigator-initiated trials.
• Continuing to fund operating needs through existing cash, revenues, potential milestone payments, and additional financing.
• Exploring strategic collaborations, business combinations, and licensing opportunities.

Key Dates

Recommendation

ADC Therapeutics shows positive product revenue growth for ZYNLONTA, indicating market traction. However, the overall revenue decline, significant ongoing net losses, and the explicit statement of needing additional capital to fund operations are considerable risks. The reduction in R&D spending, while improving short-term financials, could impact long-term pipeline development. Given these mixed signals, a 'hold' recommendation is appropriate, pending further clarity on future financing and pipeline progression.

Keywords

ADC Therapeutics, Form 10-Q, Quarterly Report, ZYNLONTA, loncastuximab tesirine-lpyl, DLBCL, Oncology, Antibody Drug Conjugates, Financial Results, SEC Filing, Biotechnology